Abstract. Mangiferin (1,3,6,7-tetrahydroxyxanthone-C2-β-D-glucoside) is a bioactive ingredient predominantly isolated from the mango tree, with potent antioxidant activity and multifactorial pharmacological effects, including antidiabetic, antitumor, lipometabolism regulating, cardioprotective, anti-hyperuricemic, neuroprotective, antioxidant, anti-inflammatory, antipyretic, analgesic, antibacterial, antiviral and immunomodulatory effects. Therefore, it possesses several health-endorsing properties and is a promising candidate for further research and development. However, low solubility, mucosal permeability and bioavailability restrict the development of mangiferin as a clinical therapeutic, and chemical and physical modification is required to expand its application. This review comprehensively analyzed and collectively summarized the primary pharmacological actions of mangiferin that have been demonstrated in the literature, to support the potential future development of mangiferin as a novel therapeutic drug.

Contents

1. Introduction
2. Potential application of mangiferin in antidiabetic therapy
3. Anti-tumor effects of mangiferin
4. The neuroprotective properties of mangiferin
5. Cardiovascular effects of mangiferin
6. Other properties of mangiferin
7. Conclusions

1. Introduction

Mangiferin, a C-glucosyl xanthone with the formula 1,3,6,7-tetrahydroxyxanthone-C2-β-D-glucoside (Fig. 1), has been extensively studied both in vivo and in vitro. It has been demonstrated to possess numerous pharmacological activities, including antioxidative, antiaging, antitumor, antibacterial, antiviral, immunomodulatory, antidiabetic, hepatoprotective and analgesic effects (1-3). Mangiferin has been detected in many plant species and may be abundantly isolated from various parts of *Mangifera indica* (mango), including the leaves, stem bark, fruit peels and root (4,5).

With advances in pharmacology and molecular biology, research regarding mangiferin has increased and more pharmacological mechanisms have been revealed, which provides further information for the design and development of mangiferin as a clinical therapeutic. However, Wang et al (6) reported that the solubility of mangiferin was only 0.111 mg/ml. In addition, Han et al (7) demonstrated that the oral bioavailability of mangiferin was only 1.2%. This may be due to its low lipophilicity properties, poor intestinal membrane permeability and low oral absorption (8). These experimental data collectively indicate that despite a wide range of pharmacological activities, mangiferin has low solubility, transmembrane permeability and bioavailability, which restricts the clinical development and application of mangiferin. In order to identify more effective therapeutic compounds, mangiferin derivatives with improved solubility, bioavailability and potency were obtained by chemical or biotransformation methods (9). Therefore, with the progress of biotechnology and research practice, mangiferin may be identified to represent a more promising, novel therapeutic drug in clinic.

Based on previous studies concerning the structural modification, pharmacological activities and therapeutic molecular
mechanisms of mangiferin in recent decades, the pharmacological effects of mangiferin were reviewed herein, in order to provide references for further drug research and development.

2. Potential application of mangiferin in anti-diabetic therapy

Prevalence and main features of diabetes mellitus. Diabetes mellitus is a common endocrine and metabolic disease that affects public health and quality of life (10,11). Statistics from the International Diabetes Federation Diabetes Atlas (http://www.diabetesatlas.org/resources/2017-atlas.html) revealed that there were an estimated 425 million adult patients with type 2 diabetes (T2D) in 2017, of whom 212 million were not diagnosed (12). Notably, China has the largest number of adult diabetic patients. The prevalence of diabetes and prediabetes in China is 11.6 and 50.1%, respectively, accounting for 113.9 million patients with diabetes and 493.4 million individuals with prediabetes, according to China’s non-communicable disease surveillance group in 2013 (13). These data indicate that diabetes has become a major public health problem worldwide.

The main feature of diabetes is hyperglycemia, which is caused by disrupted glucose homeostasis (14,15). β-cell deficiency in the pancreas results in insufficient insulin secretion and type 1 diabetes, whereas insulin resistance may lead to decreased insulin sensitivity in T2D. Glucose homeostasis requires coordinated regulation of the pancreas and insulin target organs, such as adipose tissue, muscle, the liver and the brain (15). In the pancreas, α cells secrete glucagon and β cells secrete insulin, which respond to blood glucose alterations. High glucose stimulates insulin secretion, which increases glucose uptake, use and storage in adipose and muscle tissue. Low glucose stimulates glucagon release, which promotes hepatic glucose production in the liver to increase the blood glucose levels (16). Fat cells release adipokines, including leptin, adiponectin and cytokines, as well as free fatty acids (FFA) to regulate food intake, insulin secretion and insulin sensitivity (17). The interaction between various organs or tissues associated with blood glucose regulation is essential. Disordered regulation of this system may lead to the occurrence of diabetes (18). Patients with type 1 and T2D may have progressive complications, including heart disease, stroke, blindness, diabetic nephropathy and kidney failure (19-22), if the disease is not effectively controlled. Therefore, it is necessary prevent and treat diabetes in the early stage.

Effect of mangiferin on diabetes and diabetic complications. Although drugs with multiple pharmacological mechanisms are the most effective regimens to alleviate the effects of type 2 diabetes, they cannot completely prevent disease progression (23,24). Therefore, novel and effective drugs are urgently needed. It was recently reported that mangiferin treatment was beneficial in streptozotocin (STZ)-induced diabetic mice. Biochemical, toxicological and hematological parameters were evaluated following oral treatment with 40 mg/kg mangiferin for 30 days. Compared with diabetic control mice, the levels of blood glucose, glycosylated hemoglobin, aspartate aminotransferase (AST), alanine aminotransferase (ALT) and alkaline phosphatase (ALP) were significantly reduced in mangiferin-treated diabetic mice. Furthermore, the levels of red and white blood cells were notably improved (25,26). Therefore, mangiferin was demonstrated to possess anti-diabetic efficacy without toxicity in chemically induced diabetic mice (Fig. 2A). Additionally, in a high-fat high fructose diet and STZ-induced diabetic insulin-resistant rat model, mangiferin was demonstrated to concurrently alleviate insulin resistance, improve β-cell function, reduce serum levels of triglyceride (TG), total cholesterol (TC) and low-density lipoprotein cholesterol (LDL-C), as well decrease the atherogenic index, liver TG and liver TC content. Liver glycogen content was also enhanced (27). These results validated that mangiferin may effectively improve insulin sensitivity in the treatment of type 2 diabetes accompanied with metabolic disorders (Fig. 2B).

Similarly, Muruganandan et al (28), Miura et al (29,30) and Suman et al (31) verified that mangiferin exerted significant anti-diabetic, antihyperlipidemic and antiatherogenic effects in diabetic rat models. As for the promotion of islet function induced by mangiferin, our previous study performed 70% partial pancreatectomy (PPx) in mice to elucidate the anti-diabetic mechanisms of mangiferin. The results indicated that mangiferin facilitated β-cell proliferation and islet regeneration through the regulation of crucial genes in cell cycle and islet regeneration (Fig. 2C) (32). Furthermore, our upcoming report successfully confirmed that mangiferin increases islet regeneration in young and old diabetic mice (unpublished data). Taken together, these data provide evidence that mangiferin has promising application prospects in the treatment of diabetes.

As one of the most common and serious diabetic complications, diabetic nephropathy (DN) is a renal impairment caused by diabetes-induced microangiopathy and glomerulosclerosis. Hypertension, proteinuria and hydropsy are the clinical manifestations of DN (33). Surprisingly, Pal et al (34) demonstrated that mangiferin could protect kidneys from DN. They investigated the specific mechanisms underlying the protective effects of mangiferin in a STZ-induced diabetic nephropathy rat model and observed that mangiferin markedly decreased plasma glucose, kidney to body weight ratio, blood urea nitrogen (BUN), plasma creatinine, uric acid and urinary albumin. Additionally, glomerular hypertrophy and hydropsy were attenuated following mangiferin treatment at an oral dose of 40 mg/kg body weight/day in water for 30 days (34). Similarly, in animal experiments performed by Liu et al (35) in an STZ-induced DN rat model, evidential decreases in albuminuria, BUN, kidney weight index, periodic acid-Schiff stain positive mesangial matrix area, glomerular extracellular matrix expansion and accumulation and glomerular basement membrane thickness were observed following oral mangiferin treatment (15, 30 and 60 mg/kg) for 9 weeks, via targeting of glyoxalase 1. These results validate the beneficial actions of mangiferin in DN, although body weight and blood glucose levels were not improved (35). Furthermore, mangiferin (15, 30 and 60 mg/kg/day for 9 weeks) effectively attenuated renal fibrosis through the inhibition of osteopontin overproduction and inflammation in a STZ-induced rat diabetic model (36).

Cardiovascular events may also occur in patients with T2DM, including stroke, myocardial infarction and endothelial dysfunction, which are major physical and economic burdens (37-39). Hyperglycemia-induced oxidative stress and
inflammation are thought to be involved in the development of cardiovascular disease. The activation of advanced glycation end products-receptor for advanced glycation end products (AGE-RAGE) results in increased oxidative stress, inflammation and apoptosis in ischemia-reperfusion (IR)-induced myocardial injury in diabetic rats (40). Notably, mangiferin inhibits activation of the AGE-RAGE/mitogen-activated protein kinase (MAPK), c-Jun N-terminal kinase (JNK) and p38 pathways (41). The expression of extracellular regulated kinase 1/2 (ERK1/2) in the myocardium is also increased (41). In addition, chronic treatment with mangiferin (20 mg/kg for 16 weeks) decreased the level of myocardial enzymes creatine kinase-MB and lactate dehydrogenase (LDH), as well as the inflammatory mediators tumor necrosis factor (TNF)-α and interleukin (IL)-β in the serum and left ventricular myocardium (41). In diabetic cardiomyopathy (DCM) rats, mangiferin reduces AGE production, and decreases the mRNA and protein expression of RAGE (42), suggesting that mangiferin treatment may be beneficial in DCM. A previous study determined the effect of mangiferin on myocardial IR injury in diabetic rats and further investigated the underlying mechanisms involved in its cardioprotective effects. In a diabetic rat model induced by STZ, mangiferin (60 mg/kg; oral gavage for 12 weeks) reduces blood glucose and cardiomyocyte apoptosis, downregulates inositol-requiring enzyme 1, apoptotic signal-regulating kinase and JNK (43). This suggests that mangiferin inhibits the apoptosis of myocardial cells in diabetic rats via mechanisms associated with blood glucose regulation and endoplasmic reticulum (ER) stress prevention. Endothelial dysfunction, under conditions of ER stress and increased reactive oxygen species (ROS) production, is tightly associated with cardiovascular complications in diabetes (44). The expression of thioredoxin-interacting protein (TXNIP), NLR family pyrin domain containing 3 (NLRP3), IL-1β and IL-6, as well as the phosphorylation of AMP-activated protein kinase (AMPK), was attenuated in endothelial cells cultured with mangiferin at concentrations of 0.1, 1 and 10 μM, demonstrating its inhibitory effects on TXNIP/NLRP3 inflammasome activation and it ameliorative effects on endothelial dysfunction (45).

3. Anti-tumor effects of mangiferin

The research and development of antitumor agents with fewer adverse effects has become a popular topic of research. As a monomer of traditional Chinese medicine, mangiferin has been demonstrated to have direct and auxiliary roles in oncotherapy. Mangiferin efficaciously inhibits tumor cell cycle progression. It has been widely accepted that cell growth prior to cell division is strictly controlled by the cyclin-dependent kinase 1 (CDK1)/cyclin B1 complex (46-48). Notably, mangiferin has been validated to trigger G2/M phase cell cycle arrest via regulation of the CDK1-cyclin B1 signaling pathway (49-51). DNA synthesis is accomplished during the S phase of the cell cycle, and treatment with mangiferin causes S phase delay in colorectal cancer HT29 cells and cervical cancer HeLa cells (52). In addition to its inhibitory actions on cell cycle, mangiferin induces apoptosis in tumor cells. Nuclear factor-κB (NF-κB) is a transcription factor that induces the proliferation of cancer cells (53). RelA and RelB, important members of NF-κB family, are transformed into activated NF-κB following dimerization. It was demonstrated that mangiferin inhibits the expression of RelA and RelB, activates inhibitor of NF-κB (IκB) and suppresses the phosphorylation of NF-κB kinase, thereby inhibiting the transcriptional activity of NF-κB and inducing apoptosis tumor cells (54-56). IκB kinase α and IκB kinase β-dependent IκB degradation and subsequent NF-κB activation have been widely acknowledged as the canonical NF-κB activation pathway (57). However, a collective patent review on mangiferin unveiled that multiple signaling pathways, including nuclear NF-κB signaling and cyclooxygenase-2 (COX-2) protein expression are involved in the antitumor effects of mangiferin (56). This patent review concluded that mangiferin is a candidate molecule in the development of novel antitumor drugs. Furthermore, caspase activation may participate in the apoptosis-inducing effects of mangiferin in oncotherapy. A disturbance in the balance between cell proliferation and apoptosis is known to initiate tumorigenesis (58). Caspase activation serves a critical role in apoptosis, particularly via the mitochondria-initiated pathway (59). Pan et al. (60) demonstrated that through regulation of Bcl-2, apoptosis regulator (Bcl-2) and Bcl-2 associated X, apoptosis regulator (Bax) expression, mangiferin potently inhibits tumor cell proliferation and induces apoptosis in nasopharyngeal carcinoma cells. Additionally, a study of the antitumor efficacy and underlying mechanisms of mangiferin in human cervical carcinoma HeLa cells demonstrated that the protein expression of BH3 interacting domain death agonist, Bcl-2 and pro-caspase-3 and -8 is downregulated in response to mangiferin treatment, which results in the activation of caspase-3, -7, -8 and -9, ultimately leading to apoptosis (61).

Our previous studies contributed to the understanding of the underlying molecular mechanism of mangiferin in oncotherapy (55,62,63). In human breast carcinoma MCF-7 cells, mangiferin down regulates the cyclin-dependent kinase 1-cyclin B1 signaling pathway and induces G2/M phase cell-cycle arrest to inhibit tumor cell growth (62). In addition, it was demonstrated to inhibit the protein kinase C (PKC)-NF-κB pathway to induce apoptotic cell death (62). Furthermore, in vivo experiments performed in a MCF-7 xenograft rat model confirmed the in vitro results (62). Similarly, in human lung carcinoma A549 cells, mangiferin exhibits antineoplastic properties, by inducing G2/M phase cell cycle arrest via downregulation of the cyclin-dependent kinase 1-cyclin B1 signaling pathway and inducing apoptotic cell death by inhibiting the PKC-NF-κB pathway (55). In addition, in-depth research into the underlying mechanisms of mangiferin successfully elucidated that caspase-dependent
apoptosis and obviously downregulated Notch3 expression occurs in mangiferin-treated human ovarian adenocarcinoma OVCAR3 cells (63). Based on these previous studies, it may be concluded that mangiferin exhibits prominent anti-tumor action in certain malignant neoplasms through multifactorial molecular mechanisms (Fig. 3).

4. The neuroprotective properties of mangiferin

Abundant research on the effects of mangiferin has revealed the antioxidant and anti-inflammatory properties, due to its C-glycosylxanthone structure (64). The C-glucosyl linkage and polyhydroxy component in mangiferin contributes to its free radical-scavenging activity (65). Free radicals are highly reactive molecules that are implicated in the pathology of traumatic brain injury and cerebral ischemia through oxidative stress and inflammation (66-68). In recent decades, the role of free radicals in the pathology of traumatic brain injury and cerebral ischemia has been elucidated by investigating oxidative stress and inflammation with other pathogenic processes, such as excitotoxicity, calcium overload, mitochondrial cytochrome c release, caspase activation and apoptosis in trauma and ischemia of central nervous system (CNS) (69). Furthermore, mangiferin is capable of modulating the expression of proinflammatory signaling molecules, including the expression of TNF-α and COX-2, as well as regulating various transcription factors, such as NF-κB, and NF-E2-related factor 2 (Nrf-2) (64). Research regarding the protective effects of mangiferin in CNS injury, proinflammatory cytokine expression, oxidative stress and neurobehavioral abnormalities induced by lipopolysaccharide (LPS) in cerebrum are detailed herein.

Accumulating evidence has revealed that mangiferin is able to attenuate LPS-induced cognitive deficits caused by neuroinflammation (70). Oral mangiferin pre-treatment (50 mg/kg) and treatment (50 mg/kg) following LPS injection in mice demonstrated that mangiferin ameliorates cognitive deficits by decreasing LPS-induced IL-6 expression and increasing heme oxygenase-1 (HO-1) expression in mice hippocampi. Similarly, in behavioral experiments, mice were treated with LPS (0.83 mg/kg) intraperitoneal injection following oral pretreatment with mangiferin (20 and 40 mg/kg, 14 days), which subsequently attenuated depressive and anxiety-like behaviors (71). Further research has ascertained that mangiferin increases glutathione concentration, superoxide dismutase (SOD) and catalase activity in mice; as well as decreasing lipid peroxidation and nitrite level in the hippocampus and prefrontal cortex (71). Furthermore, mangiferin reduces LPS-induced
IL-1β expression and oxidative stress when used in depressive and anxiety disorders (71). Therefore, these studies indicated that mangiferin greatly contributes to cerebral protection. By decreasing COX-2 transcript stability, mangiferin potently reduces LPS-induced prostaglandin E2 (PGE-2) synthesis and 8-iso-prostaglandin F2α (8-iso-PGF2α) production (72). Taken together, these data demonstrated mangiferin exhibits potent antioxidant and anti-inflammatory properties, by decreasing PGE-2 production, free radical formation and COX-2 synthesis.

The underlying mechanisms of neuroinflammation and oxidative damage in the brain are complicated. Young adult male Wistar rats were exposed to a high-stress environment and neurological and neuropsychiatric diseases associated with cell damage and apoptosis were observed in their cerebrum, such as neurodegenerative diseases, depression, and schizophrenia (73). It was demonstrated that mangiferin administration (15, 30 and 60 mg/kg; oral gavage) prevents hypothalamic/pituitary/adrenal (HPA) stress axis dysregulation, neuroinflammation and oxidative damage. Pretreatment with mangiferin inhibits an increase in the levels of glucocorticoids (GCs), IL-1β, TNF-α, TNF receptor 1, NF-κB, inducible nitric oxide synthase (iNOS) and COX-2 (73). Furthermore, mangiferin effectively protects against early brain injury (EBI) that is involved in the process of cerebral tissue damage induced by subarachnoid hemorrhage (SAH) (74). It was demonstrated that mangiferin decreases the mortality of animals with SAH, ameliorates neurological deficits and brain edema, attenuates SAH-induced oxidative stress and decreases cortical cell apoptosis in a dose-dependent manner. Mechanism analysis of mangiferin demonstrated that it exerts its neuroprotective effects against EBI by promoting the nuclear factor erythroid 2-related factor 2 (Nrf2)/HO-1 cascade in the mitochondrial apoptosis pathway, as well as through NLRP3 inflammasome activation and NF-κB inhibition (74). In addition, in Wistar male rats with cerebral IR injury, the activation of Nrf2/HO-1 cascade is promoted in a dose-dependent manner by mangiferin (75). Furthermore, mangiferin ameliorates the activities of SOD, glutathione and IL-10, which has a protective role in oxidative stress induced by cerebral IR injury (Fig. 4).

FIGURE 4. Overview of the neuroprotective activities of mangiferin against LPS-, stress-, SAH- and CIRI-induced models. Mangiferin has been demonstrated to exert protective effects against cognitive deficits, depression, anxiety, neuroinflammation, oxidative damage, neurological deficits and brain edema. LPS, lipopolysaccharide; SAH, subarachnoid hemorrhage; CIRI, cerebral ischemia reperfusion injury; IL, interleukin; HO-1, heme oxygenase-1; SOD, superoxide dismutase; PGE-2, prostaglandin E2; 8-iso-PGF2α, 8-iso-prostaglandin F2α; GCs, glucocorticoids; TNF-α, tumor necrosis factor-α; iNOS, inducible nitric oxide synthase; NF-κB, nuclear factor-κB; COX-2, cyclooxygenase-2; HPA, hypothalamic-pituitary-adrenal axis; Nrf2, nuclear factor erythroid 2-related factor 2; NLRP3, NLR family pyrin domain containing 3; GSH, glutathione.

5. Cardiovascular effects of mangiferin

Cardioprotective effects of mangiferin. Increasing amounts of evidence regarding the cardioprotective effects of mangiferin in isoproterenol (ISPH)-induced myocardial infarction (MI) rats has emerged. Prabhu et al (76) demonstrated that pretreatment with mangiferin (100 mg/kg) for 28 days regulates the tissues defense system against cardiac damage. Specifically, the activities of heart tissue enzymic antioxidants, including superoxide dismutase, catalase, glutathione peroxidase,
glutathione transferase and glutathione reductase, as well as non-enzymic antioxidants such as ceruloplasmin, Vitamin C, Vitamin E and glutathione, were all notably upregulated (76). It was concluded that mangiferin exerts its beneficial effects due to its antioxidant potential, which reduces myocardial oxygen consumption and relieves angina pectoris (76). In addition, mangiferin protects the myocardium against ISPH-induced MI by reducing lipid peroxide formation and retaining the activities of myocardial marker enzymes, including LDH, creatine phosphokinase (CPK), AST and ALT (77). Those results suggested that mangiferin effectively alleviates free radical release in the ischemic myocardium and delays membrane lipid oxidation. In addition, studies in myocardial cells under the condition of ISPH-induced MI demonstrated mangiferin protects the structural integrity of by reducing the effects of oxidative damage and increasing mitochondrial energy metabolism (78). Mangiferin markedly increases the activities of the tricarboxylic acid cycle and antioxidant defense enzymes in MI (78). In addition, mangiferin has been reported to prevent free radical-mediated lipid peroxidation and increase lysosomal instability, thus alleviating MI injury (79).

It has also been demonstrated that mangiferin improved heart blood flow parameters and fiber disturbance in a dose-dependent manner, following a single intravenous injection of mangiferin (5, 10 or 20 mg/kg) in a MI experimental model (80). Mangiferin administration (20 mg/kg for 4 weeks) restores the function of cardiac ejection, reduces the accumulation of TNF-α and cleaved caspase-3, and upregulates Bel-2 (80). In addition, mangiferin has a therapeutic effect on post-MI left ventricular remodeling and improves cardiac function. Mangiferin administration (50 or 100 mg/kg for 5 weeks) also protects against doxorubicin-induced mortality and electrocardiogram abnormality, decreases the expression of biochemical cardiac toxicity markers, such as dehydrogenase and creatine phosphokinase isoenzyme (81). Histopathologically, mangiferin treatment results in obvious reductions in inflammatory cell number, fibrotic area and necrotic foci (81), which indicates that mangiferin may have a preventive effect against ventricular hypertrophy and fibrosis induced by MI. Therefore, mangiferin may be used in combination with clinical treatments in the future, including with surgery or other therapeutics (Fig. 5A).

**Mangiferin in atherosclerosis and hyperlipemia.** Hyperlipidemia and elevated FFAs are risk factors for atherosclerosis, hyperlipidemia and cardiovascular disease (82). Therefore, research into the effects of mangiferin on abnormal lipid metabolism in the cardiovascular system is increasing (Fig. 5B). Atherosclerosis is closely associated with abundant oxidative events, including low-density lipoprotein (LDL) oxidation and increased intracellular reactive ROS production. Mangiferin is a polyphenol compound extracted from mango leaves and is the main active ingredient of food supplement of the flood supplement VIMANG, which is widely popular in Cuba (83). VIMANG is extracted from the bark of Mangifera indica and is typically administered as a tablet, containing 300 mg of mango bark extract (83). Oral supplementation with VIMANG, or its main polyphenol mangiferin, markedly reduces ROS generation in isolated LDL receptor (-/-) liver mitochondria and spleen lymphocytes (84). In addition, treatment prevents mitochondrial nicotinamide adenine dinucleotide phosphate hydrate (NADPH)-linked substrate depletion and NADPH spontaneous oxidation, making them suitable antioxidants with potential use in atherosclerosis susceptible conditions (84).

Guo et al (85) discovered that mangiferin (50 and 150 mg/kg) ameliorates hypertriglyceridemia by modulating the expression of genes involved in lipid oxidation and lipogenesis. Body weight, liver weight, visceral fat-pad weight, serum TG, FFA concentration, hepatic TG levels, hepatic FFA and muscle FFA contents are immensely decreased following mangiferin treatment (85). It was observed that mangiferin upregulates the mRNA levels of peroxisome proliferator-activated receptor-α, fatty acid translocase (CD36) and carnitine palmitoyl transferase 1 (CPT-1) (86). Wistar rats were fed a high-fat diet and administered mangiferin (50, 100, 150 mg/kg) simultaneously for 6 weeks, which confirmed that mangiferin improves FFA metabolism in a dose-dependent manner through promoting FFA uptake and oxidation (86). Similarly, it was also observed in Wistar rats and HepG2 cells that levels of intracellular FFA and TG accumulation was decreased in HepG2 cells. Furthermore, the AMPK pathway is associated with this therapeutic effect of mangiferin (86). Mangiferin increases the AMP/ATP ratio upstream of AMPK, decreases acyl-CoA dialcy glycerol acyltransferase 2 (DGAT2) expression, decreases acetyl-CoA carboxylase (ACC) activity. Furthermore, mangiferin promotes AMPK phosphorylation, and upregulates the expression of CD36 and CPT-1 (86). Based on the preliminary results of cell and animal experiments, Na et al (87) conducted a 12-week double-blind randomized clinical trial to evaluate the effects of mangiferin (150 mg/day) on blood lipid profiles in overweight patients with hyperlipidemia. Mangiferin supplementation substantially increases the serum levels of mangiferin, high-density lipoprotein cholesterol, L-carnitine, β-hydroxybutyrate and acetooacetate, and increases lipoprotein lipase activity. However, mangiferin did not effectivly decrease serum levels of total cholesterol, low-density lipoprotein cholesterol, serum glucose or insulin (87).

Apontes et al (88) administered mangiferin (400 mg/kg) and a high fat diet (HFD) to C57BL6/J mice for 16 weeks, demonstrating that mangiferin protects against HFD-induced weight gain, promotes aerobic mitochondrial capacity and increases thermogenesis. In addition, treatment with mangifer in overweight patients with hyperlipidemia stimulated carbohydrate oxidation and improved glucose and insulin profiles (88). The activity of mangiferin on lipogenesis regulation was further studied by proteomic analysis, in which C57BL6/J mice were fed mixed granules containing mangiferin and HFD for 18 weeks. It was demonstrated that out of 865 quantified proteins, 87 of them are differentially regulated by mangiferin. Of these proteins, ~50% are involved in energy metabolism and metabolic biosynthesis. Further classification indicated that mangiferin increases the expression of proteins that are crucial for mitochondrial biogenesis and oxidative activity, including oxoglutarate dehydrogenase E1 and cytochrome c oxidase subunit 6B1. In addition, mangiferin decreases the expression of proteins that are critical for lipogenesis, including fatty acid stearoyl-CoA desaturase 1 and acetyl-CoA carboxylase 1 (89). Taken together, these data suggest that mangiferin may be used in the treatment of metabolic disorders, by improving the protein expression profiles in mitochondrial synthesis and lipogenesis.
Mangiferin in vein endothelium. The abnormal structure and function of vascular endothelial cells are the pathological basis of many cardiovascular diseases, and vascular endothelial cells are vulnerable to a series of harmful factors (90). Under the stimulation of high blood pressure, oxidative stress and high levels of blood glucose/lipids, vascular endothelial cells synthesize and release vasodilator factors and vasoconstrictor factors, which have important roles in vascular homeostasis, thrombosis and inflammation (91). In recent decades, the protective effects of mangiferin on human umbilical vein
endothelial cells (HUVECs) have been extensively demonstrated (Fig. 5C). It has been demonstrated that mangiferin (20 µM) decreases high cellular permeability and endothelial injury induced by paraquat intoxication in HUVECs, through modulation of p120-catenin protein (92). In addition, cell survival increases in H₂O₂-treated HUVECs when mangiferin (10 and 20 µM) is administered, through its free-radical scavenging ability. A ferric reducing ability of plasma assay also demonstrated it antioxidant capacity (93). Similarly, incubation of HUVECs with glycated protein alone, or in combination with iron chelate, resulted in increased lipid peroxidation (LPO), accompanied by depletion of SOD, catalase, glutathione peroxidase and glutathione reductase levels. These data suggest that mangiferin (5 and 10 µM) has a protective effect against glycated protein-iron chelate-induced toxicity (94), which provides a promising perspective for the prevention of oxidative stress and toxicant-associated disease.

6. Other properties of mangiferin

Mangiferin in respiratory system. Mangiferin exerts protective effects against bronchial asthma and other allergic diseases. Research has demonstrated that mangiferin inhibits tracheal contractions induced by distinct stimuli, including allergens, histamine, 5-hydroxytryptamine and carbachol, in a dose-dependent manner (95). The antispasmodic effect of mangiferin on allergic and non-allergic tracheal contraction of guinea pig tracheal rings are a result of increased intracellular levels of nitric oxide synthase 3 and cyclic GMP (95). In addition, in an allergic murine experimental model, mice were orally treated with M. indica extract (50, 100 or 250 mg/kg) or mangiferin (50 mg/kg) from day 0 to 24. The results revealed that mangiferin produces a remarkable reduction in airway inflammation around vessels and bronchi, decreases immunoglobulin (Ig)E levels and lymphocyte proliferation. In addition, it was demonstrated that mangiferin inhibits IL-4 and IL-5 cytokine production in bronchoalveolar lavage fluid and lymphocyte culture supernatant (96). These experiments may be an important part of pre-clinical research that is necessary for the application of mangiferin in the treatment of respiratory diseases (Fig. 6A).

Mangiferin in liver and gallbladder disorders. Liver disease has become a major burden of human health (97). Gentiopicroside and mangiferin are regarded as two important medicinal monomers of Swertia mussotii, a herb used in Tibetan folk medicine. These may exert hepatoprotective and choleretic effects (98,99). Pal et al. (100) investigated the molecular mechanisms underlying the protective action of mangiferin against lead-induced liver injury and cellular apoptosis (100). It was revealed that mangiferin (100 mg/kg, orally for 6 days) inhibits ROS production and reduces the levels of serum marker enzymes, such as ALT and ALP. Overall, it was demonstrated that mangiferin exhibits both antioxidant and antiapoptotic properties via MAPK/NF-κB/mitochondria-dependent pathways (100).
Compared with silymarin, a standard hepatoprotective drug, the intraperitoneal pretreatment of mangiferin (30 mg/kg) possesses an extensive protective effect via reduction of serum aspartate and alanine aminotransferases, alkaline phosphatase, bilirubin and inflammatory mediator TNF-β (101). These results suggest that mangiferin exhibits potent hepatoprotective effects on CCl₄-induced liver damages in mice (101). In addition, in LPS and D-galactosamine (D-GalN)-induced acute liver injury, mangiferin upregulates the expression of Nrf2 and HO-1 in a dose-dependent manner. Furthermore, mangiferin markedly inhibits LPS/D-GalN-induced inflammatory factors, including IL-1β, TNF-α, NLRP3, apoptosis-associated speck-like protein containing a CARD and caspase-1 (102). Mangiferin treatment ameliorates fatty liver in fructose-fed spontaneously hypertensive rats (SHR) by inhibiting hepatic DGAT2, which catalyzes the final step of triglyceride biosynthesis (103). Mangiferin may enhance de novo fatty acid synthesis and oxidation in the treatment of fatty liver. Furthermore, the experiment of bile duct drainage in rats also demonstrated that mangiferin (20 mg/kg) markedly increases bile secretion and bilirubin content. In addition, gallbladder smooth muscle spasms are inhibited at a dose of 10 mg/kg (104).

Mangiferin and the immune system. The role of mangiferin in the immune system has gained increasing attention (Fig. 6C). Mangifera indica (extract containing 2.6% mangiferin) has been investigated for its immunoprotective effects, via increasing the frequency of delayed type hypersensitivity (DTH) reactions and the humoral antibody (HA) titer in mice (105). Similarly, mangiferin stimulates the immune systems and increases the resistance of Labeo rohita to Aeromonas hydrophila infection, by promoting superoxide anion, serum protein obtained from Labeo rohita and albumin production, as well as lysozyme and serum bacteridal activity (106). In order to compare the immunoprotective effects of mangiferin (the major polyphenol of Vimang) and VIMANG (an aqueous extract of Mangifera indica) on mouse antibody responses induced by inoculation with spores of microsporidian parasites, it was suggested that the components of Mangifera indica extracts may be of potential value for modulating the humoral response in different immunopathological disorders (107). However, VIMANG contains other extracts in addition to mangiferin polyphenol; therefore, the researchers may have neglected to take into account the inhibitory effects of other compounds isolated from VIMANG on the humoral response (107). In addition, mangiferin markedly suppresses tissue injury and immunotoxicity caused by cyclophosphamide treatment, through decreasing serum CKP activity and antigen-specific IgM levels (108). Thus, it was evident that mangiferin exerts an immunoprotective role via inhibition of reactive intermediate-induced oxidative stress in lymphocytes, neutrophils and macrophages (108). These data suggest that mangiferin has the potential to reduce the immunotoxicity of cyclophosphamide in oncotherapy.

The antimicrobial and antiviral effects of mangiferin. Anemarrhena asphodeloides, a plant widely used in traditional Chinese medicine, has been reported to possess antiviral and antibacterial activities (109). Mangiferin is the main effective component of Anemarrhena asphodeloides (109). In addition to its antioxidative, anti diabetic and antitumor properties, the antibacterial and antiviral effects of mangiferin are also prominent (110). Mangiferin has been demonstrated to exert antibacterial activity against two bacterial species: Staphylococcus aureus (Gram positive) and Salmonella typhi (Gram negative) (111). Through tissue culture techniques, the antiviral effects of mangiferin and isomangiferin on herpes simplex virus-1 (HSV-1) were demonstrated, with average plaque reduction rates of 56.8 and 69.5%, respectively (112). The EC₅₀ of mangiferin against herpes simplex virus-2 (HSV-2) plaque formation in HeLa cells was 111.7 μg/mL, and the therapeutic index (IC₅₀/EC₅₀) was 8.1 (113). Oral mangiferin (50 mg/kg) suppresses the growth of nematode Trichinella spiralis throughout the parasitic life cycle, by inhibiting mast cell degranulation, decreasing the serum levels of specific anti-Trichinella IgE and reducing the number of parasitic larvae (114). These studies confirm the antibacterial effects of isolated mangiferin, which may further processed as an antibacterial agent (Fig. 6D).

The main barrier for xenobiotic absorption through the skin is the stratum corneum. Research has revealed the ability of mangiferin to reversibly inhibit elastase and collagenase activity, as well as to permeate the stratum corneum and pass into the epidermis and dermis (115). As the fat and water distribution coefficient of mangiferin is relatively high, oral absorption is low (9), which suggests that mangiferin may be better absorbed through the skin.

7. Conclusions

Mangiferin has been demonstrated to possess several beneficial properties, including antioxidant, antimicrobial, anti diabetic, antiallergic, neuroprotective, cardiovascular protective, anti cancer, hypocholesterolemic and immunomodulatory effects. Although it has been regarded as a compound with extensive pharmacological activity, the pharmacodynamics of mangiferin remain unclear. Mangiferin appears to have diverse pharmacological effects. However, further clinical research into the pharmacology and pharmacokinetics of mangiferin is required, as most of these effects have only been demonstrated in in vivo and in vitro experiments. The administration of mangiferin to animals or humans will inevitably result in alterations in the body, at the molecular, cellular, tissue and/or organs level, along with its curative effects. Therefore, genomic, proteomic and metabolomic analysis should be the main strategies utilized in order to determine the pharmacodynamics of mangiferin.

The research and development of mangiferin is expected to provide novel drugs for disease treatment. However, among the numerous studies on the pharmacology of mangiferin, researchers did not use a standardized therapeutic approach. Specifically, the pharmacodynamic indexes of mangiferin in existing researches, including dose, concentration and IC₅₀, were not compared and analyzed at the same base line; therefore, the experimental results are not universal. Thus, the unified and standardized evaluation of the efficacy of mangiferin is a central component in the further exploration of pharmacodynamics and quality assurance. Furthermore, in the clinical research of mangiferin, researchers should focus on
pharmacodynamic parameters caused by its physicochemical properties, including bioavailability, half-life, adverse reactions and toxicity. In addition, further clinical trials should be implemented to allowing the broad application of this effective bioactive compound.

Acknowledgements

Not applicable.

Funding

This review was supported by the National Science Foundation of China (grant no. 81802504), the Sichuan National Science Research Fund (grant no. 2018JY0645) and Sichuan Health and Family Planning Commission Funding (grant no. 162ZD0253), and Dr. Yi Wang received funding from the Sichuan Provincial People's Hospital and a Sichuan Scientific Research Grant for Returned Overseas Chinese Scholars (grant no. 30305031014). The study was also supported by the National Key Specialty Construction Project of Clinical Pharmacy (grant no. 30305030698).

Availability of data and materials

Not applicable.

Authors' contributions

SD and HL wrote the manuscript. TL prepared the figures. XX, HW and XH searched for the relevant literature. RT and YW reviewed and edited the manuscript. All authors have read and approved the manuscript.

Ethics approval and consent to participate

Not applicable.

Patient consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

References


